Showing results (101-110 of 212) with videos related to
Sort By:
Pageof 22
Cancer Discovery|May 31, 2014
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterationsAnnan Yang, N V Rajeshkumar, Xiaoxu Wang, et al.Cancer Chemotherapy and Pharmacology|May 13, 2010
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combinationRamesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, et al.Journal of Proteome Research|December 17, 2013
Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysisMindy Porterfield, Peng Zhao, Haiyong Han, et al.Investigational New Drugs|November 9, 2012
Determinants of patient screen failures in Phase 1 clinical trialsAlexandra Mckane, Chao Sima, Ramesh K Ramanathan, et al.Investigational New Drugs|November 27, 2012
Characterization of a membrane-active anti-tumor agent, UA8967Robert T Dorr, Betty K Samulitis, Lee Wisner, et al.Biochemical Pharmacology|November 22, 2011
Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitorsLifang Xie, Michelle Kassner, Ruben M Munoz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic CancerClifford J Whatcott, Caroline H Diep, Ping Jiang, et al.Journal of Gastrointestinal Oncology|June 11, 2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trialWerner Scheithauer, Ramesh K Ramanathan, Malcolm Moore, et al.Molecular Cancer Research : MCR|October 13, 2011
Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinasesBenjamin A Katchman, Kwasi Antwi, Galen Hostetter, et al.Targeted Oncology|October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.Pageof 22